Navigation Links
Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
Date:9/26/2011

TAMPA, Fla., Sept. 26, 2011 /PRNewswire/ -- Clermont Pharmaceuticals, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today positive results from a phase III trial of non-preserved latanoprost In the study, non-preserved latanoprost was compared to Xalatan® (latanoprost ophthalmic solution) 0.005%, in subjects diagnosed with open-angle glaucoma.  Non-preserved latanoprost achieved the primary efficacy endpoint of non-inferiority to Xalatan.  In addition, non-preserved latanoprost was better tolerated than Xalatan, with statistically fewer ocular symptoms on instillation and significantly fewer subjects with conjunctival hyperemia.  Xalatan is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension; it was approved by the US Food and Drug Administration for use in 1996.  Xalatan is the registered trademark of Pfizer, Inc. 

Clermont obtained the US rights to non-preserved latanoprost from Laboratoires Thea S.A.S, an ophthalmic pharmaceutical company based in France.  Laboratoires Thea recently filed an application for European marketing authorization with the EMEA. 

Based on these positive results, Clermont intends to file a New Drug Application with the US FDA in the fourth quarter of 2011.  Clermont plans to begin discussions with potential marketing partners in the near future.   

About Open-Angle Glaucoma

Open-angle glaucoma is the most common type of glaucoma and the leading cause of blindness among adults in the US – mostly because it can progress gradually and go unnoticed for years.  An increase in eye pressure occurs slowly over time.  This pressure pushes on the optic nerve and the retina at the back of the eye.  The cause of open-angle glaucoma is unknown, but it tends to be hereditary, with people of African descent at particularly high risk. 

About Clermont Pharmaceuticals

Clermont Pharmaceuticals, Inc. is a privately held Florida based ophthalmic pharmaceutical company focused on the development of new medicines for the treatment glaucoma. 

About Laboratoires Thea

Laboratoires Thea was founded in 1994 and is managed by Henri and Jean-Frederic Chibret. Laboratoires Thea is a 350 MUSD ophthalmic pharmaceutical company and is the leading independent ophthalmic group in Europe and is committed to the development and marketing of innovative ophthalmic drugs, medical devices, and nutraceuticals.


'/>"/>
SOURCE Clermont Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces Efficacy and Safety of EXPAREL™ Highlighted at "Hot Topics in Plastic Surgery" Panel at the 2011 Annual Meeting of the American Society of Plastic Surgeons
2. Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
3. Zacks Industry Outlook Highlights: Vertex Pharma, AstraZeneca, Abbott Labs, Allergan and Onyx Pharmaceuticals
4. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
5. Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
6. Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine
7. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
8. Isis Pharmaceuticals and BioMed Realty Trust Celebrate Grand Opening of New R&D Facility in Carlsbad, California
9. CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001
10. Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing
11. Valeant Pharmaceuticals to Refinance Senior Secured Credit Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Leading ... 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... in the life sciences, offering exclusive access to key decision makers who influence ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the first physician ... spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as ... the first in Arkansas to introduce the most powerful SCS system and the only ...
(Date:5/26/2017)... ... ... A new analysis of community health data reveals that four out of the ... the average cost of healthcare rising and the U.S. senior population expected to double ... of where they live. An annual 2017 report looked at a variety of community ...
(Date:5/26/2017)... ... 26, 2017 , ... via seating is proud to partner ... chair specifically designed for clinical areas. Genie Copper Mesh is a crossover chair ... to provide customers with a game changing chair that is affordably priced,” Chas ...
(Date:5/26/2017)... ... May 26, 2017 , ... After raising nearly $30,000 on Kickstarter ... to be available at a discounted crowdfunding price on Indiegogo . , “Along ... I also wanted to bring a fidget toy to the market that was made ...
Breaking Medicine News(10 mins):